FDA Panel Leans In Favor Of Expanded Indication For Abbott’s Carotid Stent
This article was originally published in The Gray Sheet
Executive Summary
An FDA advisory panel provided support for Abbott's bid to expand labeling for its RX Acculink carotid stent system to treat a larger patient population, despite reservations from some members about safety.